COMTAN

LOE Approaching

entacapone

NDAORALTABLET
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12

Mechanism of Action

Catechol O-Methyltransferase Inhibitors

Pharmacologic Class:

Catechol-O-Methyltransferase Inhibitor

Clinical Trials (5)

NCT00601978Phase 4Withdrawn

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

Started Aug 2008
0
Parkinson's Disease
NCT00642356Phase 4Terminated

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

Started Mar 2008
14 enrolled
Parkinson's Disease
NCT00391898Phase 4Completed

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

Started Oct 2006
95 enrolled
Parkinson's Disease
NCT00415922Phase 1Completed

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers

Started Jul 2006
42 enrolled
Healthy
NCT00415844Phase 1Completed

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers

Started Jun 2006
42 enrolled
Healthy